Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
March 01 2022 - 8:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma," “Connect,” or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
the appointment of Chin Lee, MD, MPH, as Chief Medical Officer,
effective March 1, 2022.
“We are delighted to welcome Dr. Lee to
Connect’s executive team at a pivotal time for the organization,”
said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma.
“His extensive drug development experience in inflammation and
immunology is expected to help advance our clinical pipeline of
potentially differentiated therapeutic candidates designed to
improve care and outcomes for millions of people with inflammatory
diseases worldwide.”
Dr. Lee brings more than 15 years of clinical
research and development experience in the biopharmaceutical
industry. Prior to joining the Company, Dr. Lee served as Vice
President, Head of Clinical Science, and Chief Medical Officer at
Theravance Biopharma, Inc. Before this role, Dr. Lee was Lead Group
Medical Director, within the Genentech Research & Early
Development (gRED) group at Genentech, Inc. Previously, Dr. Lee
held roles of increasing responsibility at Eli Lilly & Company,
serving most recently as Global Senior Medical Director, Immunology
Therapeutic Area, within the Bio-medicines Business Unit, and he
also served as Associate Medical Director, Immunoscience Group, at
Abbott. He has successfully led the submission of global regulatory
filings, including for U.S. Food and Drug Administration approvals,
and product commercialization across multiple autoimmune and
immunology disease indications. Dr. Lee received a B.S. in Biology
and an M.D. from the University of North Carolina at Chapel Hill
and an M.P.H. from Northwestern University.
“I am honored to join Connect Biopharma during
this exciting time as they progress their pipeline of innovative
development programs derived from their T cell-driven research,”
said Dr. Lee. “Connect is a leader in targeting immunological
pathways, and I look forward to working with my new colleagues to
discover and develop potential best-in-class therapies for
inflammatory diseases.”
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, an antibody
designed to target interleukin-4 receptor alpha (IL-4Rα), has been
in clinical trials for the treatment of atopic dermatitis (AD),
asthma, and chronic rhinosinusitis with nasal polyps. Our second
lead product candidate, CBP-307, a modulator of a T cell receptor
known as sphingosine 1-phosphate receptor 1 (S1P1), has been in
clinical trials for the treatment of ulcerative colitis and Crohn’s
disease. Furthermore, we have started the clinical development of
an additional product candidate, CBP-174, a peripherally acting
antagonist of histamine receptor 3, for the treatment of pruritus
associated with AD.
With clinical development activities in the
United States, China, Europe, and Australia, and operations in
those geographies as well as Hong Kong, Connect Biopharma is
building a rich global pipeline of internally designed, wholly
owned small molecules and antibodies targeting several aspects of T
cell biology. For additional information about Connect Biopharma,
please visit our website at www.connectbiopharm.com.
FORWARD-LOOKING STATEMENTS
Connect Biopharma cautions that statements
included in this press release that are not a description of
historical facts are forward-looking statements. Words such as
"may," "could," "will," "would," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "intend," "predict," "seek,"
"contemplate," “look forward,” "potential," "continue" or "project"
or the negative of these terms or other comparable terminology are
intended to identify forward-looking statements. These statements
include the Company’s plans to advance the development of its
therapeutic candidates and the potential of such therapeutic
candidates, if approved, to be best-in-class products. The
inclusion of forward-looking statements shall not be regarded as a
representation by Connect Biopharma that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the Connect
Biopharma business and other risks described in the Company's
filings with the Securities and Exchange Commission (“SEC”).
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Connect Biopharma undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included in Connect Biopharma's filings with the SEC which are
available from the SEC’s website (www.sec.gov) and on Connect
Biopharma’s website (www.connectbiopharm.com) under the heading
"Investors." All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under
the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
IR/PR Contacts: Lazar FINN
Partners David Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comErich Sandoval (Media)T:
+1-(917)-497-2867erich.sandoval@finnpartners.comCorporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2023 to Apr 2024